Autism is not a single condition and there is no cause, scientists conclude
New research from The University of Cambridge suggests that autism must not be understood as a homogeneous condition of a single cause. Scientists have discovered that people are diagnosed in early childhood often have a different genetic profile than those diagnosed later in life, spreading understanding how the condition is developing.
The study analyzed the behavior of the autistic nation during childhood and adolescence in the UK and Australia. He also assessed the genetic data of more than 45,000 patients with the situation from different cohorts in Europe and the United States.
By connecting genetic information to age in diagnostics, researchers have noticed that the profiles of those who were different early to the situation differed early from those who received confirmation in later phases. They found only mild overlap between the two groups, which indicates that biological mechanisms are associated with autism may differ from those associated with autism identified in adolescence or adult.
Analysis, posted last week in the magazine NatureThey showed that children were diagnosed six years ago more likely to have behavioral difficulties – such as social interaction problems – from early age. In contrast, those diagnosed after 10 years were more likely to experience social and behavior difficulties during adolescence. They also had a larger predisposition in mental health conditions, such as depression.
The study adds that the average genetic profile of those diagnosed later was closer to the ADHD and the conditions such as post-traumatic stress disorder than the “classical” autism identified in early childhood.
The study concludes that timing diagnosis is not fully randomly, but reflects the fundamental genetic differences that match the risk for other conditions in some cases.
“We first discovered that the autism was diagnosed even later,” said Varun Warrier, a researcher at the Psychiatry Department at the University of Cambridge and the paper guide, in the press statement. “The term” autism “probably describes more conditions.”
This launch wants to put your brain-computer interface in the Apple Vision Pro
Now, Kognixion brings its and communication app on Vision Pro, which Forsland says that there is more functionality than the purpose built-in Axon-R. “Vision Pro gives all your apps, App Store, everything you want to do,” he says.
Apple has opened the door to integrating May, when announced a new protocol to allow users to serious disabilities for mobility to control iPhone, iPad and Vision Pro without physical movement. Another company BCI, Synchron, whose implant is inserted into a bloodship next to the brain, also integrated its system with the Vision Pro. (Apple is not known to develop own BCI.)
At the trial of the Kognixion, the company has replaced Apple’s headband, which is incorporated with six electroencephalographic, or EEG, sensors. They collect information from the visual and parietary cortex of the brain, which are located on the back of the head. In particular, the Cognixion system identifies visual fixation signals, which occur when a person maintains a view of the facility. This allows users to choose from the menu option in the interface only using mental attention. Neural computer package carried in the side of the data processes outside the vision of the pro.
“The philosophy of our approach is about reducing the amount of cargo generated in the person’s communication needs,” says Chris Ullrich, Chief Officer Kognixion.
Current communication tools can help but are not ideal. For example, low-technological handbound plates allow patients to look at certain letters, words or images so the caretaker can guess their meaning, but those who consume. And eye tracking technology is still expensive and is not always reliable.
“We are actually building and for each individual participant who is adapted to their history, their style of their humor, what we can gather in something that is okay what is a user proxy”, it is said in something that is user proxy “, it is said in something that is user Proxy, “he says in the name of the user,” he is said in something that is user proxy “, it is said in something that is user proxy”, it is said in something that is user proxy.
Started used AI to make a psychedelic without travel
While there is a growth Evidence that psychedelic medications can effectively treat mental health conditions, especially in cases where traditional treatments failed, they continue to come with minorities.
Their hallucinogenic effects can be intimidating and irresistible, and dosing sessions last several hours. A good treatment rely heavily in the way of thinking of an individual who goes into a session and the environment in which they received it. And although it is rare, psychedelics can sometimes worsen the existing mental illness.
Mindstate Design Laboratories is one of the slate of new companies that aim to make more safer psychedelike by removing the classic “travel” associated with them. The company uses AI to help design psychedelic medications that cause specific mental conditions without hallucinations, and its first layer looks promising.
“We have created the least psychedelic-psychedelic that is psychoactive,” says the Director General Dillan Dinardo. “That’s pretty psychoactive, but there’s no hallucinations.”
It was founded in 2021. and supported the Y Combinator and the founders of Openai, Neurilink, InstaCart, coinbase, and a set of models with various psychic drugs in more than 70,000 “reports” from the official media, red, and even dark internet.
Platform analysis How psychedelics produce different effects to drafting the first drug candidate, MSD-001, ownership oral Formulation of 5-MEO-MIPTA, also known as the Moxy street. At the trial phase divided by wired, the drug was safe and well tolerated into five different dose in 47 healthy participants. He also produced psychoactive effects without causing the flexibility of the mind, which the company says is the validity of his AI platform.
While the participants reported enhanced emotions, associative thinking, improved imagination and perceptions like colors look lighter, they did not experience hallucinations, independent disintegration, ocean boundless travel and other typical characteristics of psychedelic travel.
The company measures the effects of medicines with valid scales used in psychedelic research and requested participants in subjective issues such as “Are you happy?” And “are you sad?” The researchers also noticed the stability of the eyes of volunteers and performed brain recording before, during and after psychoactive effects. Using this information about the imagination of the brain, the company managed to determine that the medicine produced many of the same brain-related brain forms and other first-generation psychodelial. “The medicine enters the brain and do what we intend to do,” Dinardo says.
Psychoactive effects have started within about 30 minutes after participants took medicine, with peak intensity that occur about an hour and a half to two hours. The company does not report serious harmful events.
The trial that happened in the Human Drug Research Center in the Netherlands included a combination of individuals who tried psychedelike in the past and others who did not have.
Mindstate’s approach is based on the idea that the psychedelic “excursion” may not be needed for therapeutic benefits. Psychedes work on serotonin brain promoting neuroplasticity, which includes growth of neurons and form new ties. Some researchers believe that this ability to encourage neuroplasticity, not hallucinogenic effects the key to the treatment of mental illness.